GlassScriptPhysician profile
Debbie L Flaherty
NPI 1831401413
$783.56
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $159.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $185.92 | 2019-2020 | |
| Abbvie INC. | $133.96 | 2019-2020 | |
| Celgene Corporation | $113.20 | 2019 | |
| Sun Pharmaceutical Industries INC. | $83.90 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $59.67 | 2019-2020 | |
| Genzyme Corporation | $56.80 | 2019-2020 | |
| Pfizer INC. | $31.80 | 2019 | |
| Prugen, INC. Pharmaceuticals | $29.49 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $26.60 | 2019 | |
| Lilly USA, LLC | $23.08 | 2020 | |
| Mission Pharmacal Company | $23.03 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.